Ratings Alvotech Nyse

Equities

ALVO

LU2458332611

Market Closed - Nyse Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
11.98 ^USD	-1.32%		-0.91%	+27.72%

11/07	Alvotech Closes $965 Million Loan Facility	MT
11/07	Alvotech Closes $965 Million Loan Facility	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
The company is highly valued given the cash flows generated by its activity.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALVOTECH	+27.72%	366.19Cr	-
MODERNA, INC.	+24.74%	4.8TCr	B-
IQVIA HOLDINGS INC.	-0.47%	4.24TCr	B
LONZA GROUP AG	+43.96%	4.15TCr	A
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.16TCr	B
ICON PUBLIC LIMITED COMPANY	+17.96%	2.86TCr	B-
CELLTRION, INC.	-4.47%	2.8TCr	C
UNITED THERAPEUTICS CORPORATION	+50.73%	1.46TCr	B+
MEDPACE HOLDINGS, INC.	+42.56%	1.41TCr	C+
BIO-TECHNE CORPORATION	+1.46%	1.26TCr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes